REG - Hutchison China Medi - Notification of Dilution of Voting Rights

HUTCHMED (China)Announcement

07/07/2020 07:01

RNS Number : 1450S
  
Hutchison China Meditech Limited
  
07 July 2020
  
 

Notification of Dilution of Voting Rights
 
 
London: Tuesday, July 7, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares"). 
 
Each American Depositary Share ("ADS") represents five Shares.  As announced on June 25, 2020, Chi-Med issued a total of 20,000,000 Shares (equivalent to 4,000,000 ADSs) to General Atlantic.  Chi-Med was notified on July 6, 2020 that this issuance diluted CK Hutchison's holding1 to 46.79 per cent of the total number of voting rights of Chi-Med.  The date on which the notification threshold was crossed was July 3, 2020.
 
 
About CK Hutchison
 
Listed on The Stock Exchange of Hong Kong Limited, CK Hutchison is a renowned multinational conglomerate committed to innovation and technology with businesses spanning the globe.  With operations in about 50 countries and over 300,000 employees worldwide, CK Hutchison has five core businesses - ports and related services, retail, infrastructure, energy and telecommunications.  
 
CK Hutchison reported turnover of approximately HK$440 billion (US$56 billion) for the year ended 31 December 2019.
 
For more information, please visit www.ckh.com.hk. 
 
 
About Chi-Med
 
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China.  For more information, please visit: www.chi-med.com.
 
 
[1] Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.
 
CONTACTS
 



Investor Enquiries








Mark Lee, Senior Vice President


+852 2121 8200




Annie Cheng, Vice President


+1 (973) 567 3786














Media Enquiries


 




Americas - Brad Miles, Solebury Trout


+1 (917) 570 7340 (Mobile) 
bmiles@troutgroup.com




Europe - Ben Atwell / Alex Shaw, FTI Consulting


+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Chi-Med@fticonsulting.com




Asia - Joseph Chi Lo / Zhou Yi, Brunswick


+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com














Nominated Advisor








Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited


+44 (20) 7886 2500



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TVRUNVRRRKUBRAR